Decrease in fasting insulin secretory function correlates with significant liver fibrosis in Japanese non-alcoholic...

Area of Science:

• Hepatology
• Endocrinology
• Metabolic Syndrome

Background:

• Non-alcoholic fatty liver disease (NAFLD) is linked to metabolic syndrome and diabetes, with insulin resistance playing a key role.
• The precise relationship between insulin secretion and NAFLD progression, especially fibrosis, remains incompletely understood.
• Investigating insulin secretory function (ISF) offers potential insights into NAFLD pathogenesis.

Purpose of the Study:

• To evaluate the association between fasting insulin secretory function (ISF), assessed by homeostatic model assessment-beta cell function (HOMA-β), and the severity of liver fibrosis in NAFLD patients.
• To characterize the relationship between HOMA-β values and clinical parameters, including hepatic fibrosis stage.

Main Methods:

• The study included 188 patients with biopsy-confirmed NAFLD.
• Fasting insulin secretory function was quantified using the homeostatic model assessment-beta cell function (HOMA-β).
• Log HOMA-β values were analyzed for correlations with clinical parameters, focusing on hepatic fibrosis severity.

Main Results:

• Log HOMA-β was significantly lower in NAFLD patients with advanced fibrosis (stages 2-4) compared to those with early fibrosis (stages 0-1).
• The prevalence of significant fibrosis showed an inverse relationship with increasing Log HOMA-β.
• Lower Log HOMA-β was associated with lower body mass index (BMI) values, including current, 20-year-old, and peak lifetime BMI.

Conclusions:

• Fasting insulin secretory function (ISF) diminishes as liver fibrosis progresses in NAFLD.
• Impaired beta cell function, indicated by lower HOMA-β, is a characteristic finding in significant liver fibrosis within NAFLD.
• These findings are particularly relevant for relatively non-obese Japanese patients with NAFLD.